Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guillermo Alcaín

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Inflammatory Bowel Diseases|June 13, 2015
Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines WithdrawalEstefanía Moreno-Rincón, José Manuel Benítez, Francisco Javier Serrano-Ruiz, et al.
Gastroenterologia Y Hepatologia|December 25, 2017
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patientsManuel Barreiro-de Acosta, Ignacio Marín-Jiménez, Abel Panadero, et al.
World Journal of Gastroenterology|November 19, 2025
Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel diseaseAntonio J Ruiz-Malagón, Marina Herraiz-Vilela, Raquel Serrano-Pino, et al.
Scientific Reports|July 2, 2025
Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosisFlores Martín-Reyes, Imane Kentaoui-Bousellam, Antonio Jesus Ruiz-Malagón, et al.
Journal of Clinical Medicine|July 9, 2022
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCUSabino Riestra, Carlos Taxonera, Yamile Zabana, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
The American Journal of Gastroenterology|January 2, 2025
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment PersistenceAntonio Giordano, Isabel Pérez-Martínez, Javier P Gisbert, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Inflammatory Bowel Diseases|June 13, 2015
Prognosis of Patients with Ulcerative Colitis in Sustained Remission After Thiopurines WithdrawalEstefanía Moreno-Rincón, José Manuel Benítez, Francisco Javier Serrano-Ruiz, et al.
Gastroenterologia Y Hepatologia|December 25, 2017
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patientsManuel Barreiro-de Acosta, Ignacio Marín-Jiménez, Abel Panadero, et al.
World Journal of Gastroenterology|November 19, 2025
Growth differentiation factor 15 alters intestinal barrier and increases permeability: A new molecular target in inflammatory bowel diseaseAntonio J Ruiz-Malagón, Marina Herraiz-Vilela, Raquel Serrano-Pino, et al.
Scientific Reports|July 2, 2025
Mesenteric adipose tissue in Crohn's disease alters the immune response of the ileal mucosa and increases angiogenesis and fibrosisFlores Martín-Reyes, Imane Kentaoui-Bousellam, Antonio Jesus Ruiz-Malagón, et al.
Journal of Clinical Medicine|July 9, 2022
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCUSabino Riestra, Carlos Taxonera, Yamile Zabana, et al.
Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
Inflammatory Bowel Diseases|September 11, 2019
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida RegistryMaría José Casanova, María Chaparro, Miguel Mínguez, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
The American Journal of Gastroenterology|January 2, 2025
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment PersistenceAntonio Giordano, Isabel Pérez-Martínez, Javier P Gisbert, et al.
Pageof 2